Pemphigus: Current and Future Therapeutic Strategies.

Area of Science:

• Immunodermatology
• Autoimmune Blistering Diseases
• Pathogenesis of Pemphigus

Background:

• Pemphigus is a chronic autoimmune disease causing skin and mucous membrane blisters due to IgG autoantibodies targeting desmogleins (Dsg).
• While glucocorticoids improved prognosis, long-term use and immunosuppressants carry risks, including infections.
• Rituximab, an anti-CD20 monoclonal antibody, is now a first-line therapy, improving survival and remission rates.

Purpose of the Study:

• To review current advances in pemphigus management.
• To highlight unmet challenges in treating this autoimmune condition.
• To discuss future perspectives for pemphigus therapy.

Main Methods:

• Review of current literature on pemphigus pathogenesis and treatment.
• Analysis of the role of B-cells and T-cells in pemphigus.
• Exploration of novel therapeutic strategies.

Main Results:

• B-cell depletion with rituximab improves pemphigus outcomes, leading to faster prednisone tapering.
• T-cell dysfunction can follow B-cell depletion, suggesting a complex immune interplay.
• Dsg-specific T-cell clones are critical in initiating the inflammatory response and B-cell activation.

Conclusions:

• Rituximab offers significant benefits in pemphigus treatment, but long-term management requires addressing T-cell roles.
• Future therapies may focus on restoring immune tolerance to desmogleins.
• Monitoring autoreactive T-cells could guide personalized pemphigus treatment strategies.